logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Indegene Ltd

Indegene

Mid Cap•4,141 Employees•IPO 2024
Current Price
₹471.60
-8.35 (-1.74%)Updated
NSE :INDGN
BSE :544172
Sector :Life Sciences Tools & Services
Today's Range
₹460.80
₹471.60
union icon
₹481.65
52 Week Range
52W Low₹455.60
52W High₹632.90
₹471.60
union icon
Downside3.51%
Upside34.20%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹11,971.64 Cr
Market Cap
Total market value of company
P/E Ratio
25.92
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
4.70
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹18.23
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
8.02%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
24.80%
ROCE
Return on Capital Employed. >15% is good
Net Margin
13.46%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
-%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
-%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
12.50%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
32.70%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.04
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹109.15
Book Value
Net asset value per share
Dividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
0.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

4 points
  • •Indegene Ltd demonstrates strong profitability with a Return on Equity (ROE) of 20.6% and an impressive Return on Capital Employed (ROCE) of 24.8%, indicating efficient capital utilization and superior operational performance, generating healthy returns for shareholders.
  • •The company exhibits robust growth, with quarterly profit increasing by 32.7% and quarterly sales growing by 12.5%. This consistent expansion highlights strong market demand and effective business strategies, driving revenue and earnings.

Weaknesses

4 points
  • •A significant concern for Indegene Ltd is the 0% promoter holding, which raises questions about long-term commitment and potential governance issues. This lack of promoter stake could impact investor confidence and stock stability.
  • •Indegene's Price-to-Earnings (PE) ratio of 30.20 appears relatively high, suggesting the stock might be overvalued compared to its current earnings. Investors should carefully assess this valuation against future growth prospects.

Opportunities

3 points
  • •Operating in the 'Healthcare Research Analytics & Technology' sector presents significant growth opportunities, driven by increasing digitalization in healthcare and demand for data-driven solutions globally, expanding market potential.
  • •The notable increase in FII holdings from 3.79% to 11.30% and DII holdings from 3.84% to 6.95% over the past year signals growing institutional investor confidence, potentially attracting more capital and boosting valuation.

Threats

4 points
  • •The 'Healthcare Research Analytics & Technology' sector is highly competitive, with established players and new entrants. Intense competition could pressure Indegene's margins and market share, impacting future profitability.
  • •The stock's significant price range, from a 52-week high of ₹735 to a low of ₹485, indicates considerable market volatility. This exposes investors to potential sharp declines, especially during broader market corrections.

Segment-wise Financial Analysis

Financial Results

Balance Sheet

Standalone • Annual • All amounts in ₹ Crores • CA Schedule III Format

No Balance Sheet Data Available

Standalone annual data is not available for this symbol.
Try switching to Consolidated view.

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

Recent Insider Transactions

Insider NameTransaction DateFiling DateTotal SharesChangePriceAction
Rajesh Bhaskaran Nair
17 Dec 202418 Dec 20241.72 Cr
1.00 L
₹595.81BUY
Rajesh Bhaskaran Nair
23 Dec 202423 Dec 20241.72 Cr
25,000
₹598.26BUY
Sanjay Suresh Parikh
20 Dec 202423 Dec 20241.20 Cr
16,500
₹606.52BUY
Manish Gupta
24 Dec 202427 Dec 20242.15 Cr
17,000
₹599.19BUY

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹523.60+₹52.00+11.03%
R3₹502.75+₹31.15+6.61%
R2₹492.20+₹20.60+4.37%
R1₹481.90+₹10.30+2.18%
PIVOT₹471.35-0.25-0.05%
CURRENT₹471.60--
S1₹419.35-₹52.25-11.08%
S2₹440.20-₹31.40-6.66%
S3₹450.50-₹21.10-4.47%
S4₹461.05-₹10.55-2.24%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
4.24L
(04 Mar 2026)
-5.0% vs avg
Delivery %
54.5%
(04 Mar 2026)
-7.5% vs avg
Avg Volume (20D)
4.46L
(04 Feb - 04 Mar)
20-day average
Avg Delivery %
62.0%
(04 Feb - 04 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Divis Laboratories Ltd
1.64L ₹ Cr
Best Profit Growth
Sai Life Sciences Ltd
548.00 %
Highest Dividend Yield
Windlas Biotech Ltd
1.29 %

Peer Comparison

Company Name
AKUMS
Akums Drugs & Pharmaceuticals Ltd
ANTHEM
Anthem Biosciences Ltd
DCAL
Dishman Carbogen Amcis Ltd
DIVISLAB
Divis Laboratories Ltd
INNOVACAP
Innova Captab Ltd
ONESOURCE
OneSource Specialty Pharma Ltd
SAILIFE
Sai Life Sciences Ltd
SUVEN
Suven Life Sciences Ltd
SYNGENE
Syngene International Ltd
VIMTALABS
Vimta Labs Ltd
WINDLAS
Windlas Biotech Ltd

About

INDGN

Indegene Ltd

Indegene Limited is a global digital-first life sciences commercialization company headquartered in Bengaluru, India, with a significant presence in the United States and Europe. The company's core business revolves around providing comprehensive services and technology solutions to biopharmaceutical, emerging biotech, and medical device companies across their entire product lifecycles.

Indegene's operations are structured into three primary segments: Enterprise Medical Solutions, Enterprise Commercial Solutions, and Omnichannel Activation & Others. The Enterprise Medical Solutions segment focuses on providing medical and clinical solutions, supporting the development and regulatory aspects of new products. This likely includes services such as medical affairs, regulatory strategy, and clinical trial support.

The Enterprise Commercial Solutions segment caters to the commercial aspects of bringing products to market. This likely encompasses services such as market research, sales force effectiveness, pricing and market access strategy, and overall commercial strategy development and execution. These services are crucial for maximizing product uptake and return on investment.

The Omnichannel Activation & Others segment likely incorporates a range of solutions aimed at integrating various channels for effective communication and engagement with healthcare professionals and patients. This might include digital marketing, content creation, and multi-channel campaign management to promote products and build brand awareness. The "Others" component likely encompasses additional services that complement the core offerings, potentially including consulting or specialized technology services.

A key aspect of Indegene's business model is its reliance on NEXT technology platforms. These platforms likely represent a suite of proprietary technologies and tools designed to enhance efficiency and effectiveness across its various service offerings. These platforms could include data analytics dashboards, CRM systems tailored for the life sciences industry, or other specialized software.

In summary, Indegene acts as a comprehensive partner for life sciences companies, providing a blend of consulting, technology, and services to navigate the complexities of research, development, and commercialization. Their integrated approach across medical, commercial, and omnichannel activation ensures a holistic support system for clients throughout the entire product lifecycle.

COMPANY FACTS - INDGN

Registered Address

Aspen Block G4, 3rd Floor, Manyata Embassy Business Park, Outer Ring Road, Nagawara

Bangalore

KARNATAKA

IN

Tel: 918046744567

Website:https://www.indegene.com/

Investor Relations:https://www.indegene.com/investor-relations
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Life Sciences Tools & Services

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 4,141

IPO Date: 13/05/2024

MANAGEMENT - INDGN

Mr. Manish Gupta

Executive Chairman of the Board, Chief Executive Officer

Mr. Suhas Prabhu

Chief Financial Officer

Dr. Sanjay Parikh

Executive Vice President, Executive Director

Mr. Anand Nijegal

Executive Vice President - Global Operations

Ms. Srishti Kaushik

Compliance Officer, Company Secretary

Mr. Viveksheel Ghai

Executive Vice President - Enterprise Commercial Solutions of Indegene, Inc.

Mr. Gaurav Kapoor

Executive Vice President of Indegene, Inc.

Mr. Sameer Lal

Senior Vice President - Business Development of Indegene, Inc.

Mr. Neeraj Bharadwaj

Non-Executive Nominee Director

Mr. Mark Dzialga

Non-Executive Nominee Director

Dr. Rajesh Nair

Non-Executive Director, President of Indegene, Inc.

Mr. Pravin Bhadya Rao

Non-Executive Independent Director

Investor Questions Answered

Indegene Ltd (INDGN) Stock FAQs

Get answers to the most common questions about Indegene Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Indegene Ltd (INDGN) is ₹471.6. Today, the stock has declined by ₹8.35 (1.74%), trading in a range of ₹460.8 to ₹481.65. The stock opened at ₹470.6 with a trading volume of 4,24,205 shares.
Indegene Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹11,971.64 crores, P/E ratio of 25.92, ROE of 8.02%, and ROCE of 24.80%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Indegene Ltd (INDGN) is ₹632.9, while the 52-week low is ₹455.6. Currently trading at ₹471.6, the stock is 9.0% away from its 52-week low and 25.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Indegene Ltd stock at ₹471.6 depends on multiple factors. The stock is currently trading with a P/E ratio of 25.92 and P/B ratio of N/A. Today's performance shows a loss of 1.74%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Indegene Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹471.6, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Indegene Ltd's key financial metrics include: P/E Ratio: 25.92, P/B Ratio: N/A, ROE: 8.02%, ROCE: 24.80%, Dividend Yield: 0.00%, EPS: ₹18.23, Book Value: ₹109.15, Debt-to-Equity: 0.04, and Current Ratio: N/A. The company's market cap stands at ₹11,971.64 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Indegene Ltd stock opened at ₹470.6 and is currently trading at ₹471.6, showing a decline of ₹8.35 (1.74%). The intraday high is ₹481.65 and low is ₹460.8. The trading volume stands at 4,24,205 shares, indicating moderate market participation today.
Indegene Ltd has a Price-to-Earnings (P/E) ratio of 25.92, which means investors are willing to pay ₹25.92 for every ₹1 of earnings. With an EPS of ₹18.23, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Indegene Ltd has a market capitalization of ₹11,971.64 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹471.6) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Indegene Ltd has a book value of ₹109.15 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹471.6, which is 332.1% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Indegene Ltd has a Return on Equity (ROE) of 8.02% and Return on Capital Employed (ROCE) of 24.80%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Indegene Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Indegene Ltd has a debt-to-equity ratio of 0.04, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Indegene Ltd has an Earnings Per Share (EPS) of ₹18.23, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹471.6 and P/E ratio of 25.92, investors are paying 25.92 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Indegene Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Indegene Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Indegene Ltd stock, consider: 1) Fundamental Analysis - Review P/E (25.92), ROE (8.02%), debt-to-equity (0.04), and growth rates. 2) Technical Analysis - Check 52-week range (₹455.60 - ₹632.90), moving averages, and chart patterns. 3) Valuation - Compare current price (₹471.60) with book value (₹109.15) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Indegene Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹471.6 is 23480x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Indegene Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹455.60 - ₹632.90). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.04 indicates leverage. 4) Liquidity Risk - Based on trading volume of 4,24,205 shares. 5) Valuation Risk - P/E of 25.92 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Indegene Ltd operates in the industry with key metrics: P/E ratio of 25.92, ROE of 8.02%, market cap of ₹11,971.64 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.04), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Indegene Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹471.6, with a 52-week range of ₹455.60 to ₹632.90. Based on fundamentals like P/E (25.92), ROE (8.02%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Indegene Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹471.60. 2) Fundamental Deterioration - Declining ROE (currently 8.02%), increasing debt (D/E: 0.04), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Indegene Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.